How are clinical trials run on time, on budget, and in GCP compliance?
We take operational ownership of clinical trials for pharma, biotech, and medtech: milestone and budget control, site activation and recruitment, CRO coordination, and management of the Trial Master File in line with ICH E6 and the Clinical Trials Regulation (EU) No 536/2014. Trials rarely go off the rails because the protocol is wrong, but because site activation sits on the critical path: those who parallelize contract negotiation, ethics approvals, and initiation instead of running them sequentially win back the time that would otherwise be missing later during recruitment.
- Pharma
- Biotech
- MedTech
Overview
Where does the operational leadership of clinical trials break down?
Trial leadership from Phase I through post-market · ICH E6 (GCP), EU 536/2014 (CTR), EU 2017/745 (MDR), ISO 14155:2020
Last updated: 2026-06-13
Clinical trials rarely fail on design and usually fail on operational leadership: on handovers that never happen, on sites activated too late, and on a Trial Master File that is only filled in just before the inspection. The points where trial projects most often lose time and budget:
- Weak milestone and budget management without defined escalation rules: delays only become visible once the critical path has already broken, not while corrective action is still inexpensive.
- Site activation and recruitment are run sequentially rather than in parallel: long lead times for contracts, ethics approval, and initiation push back the recruitment start and jeopardize enrollment targets.
- The Trial Master File is not maintained throughout the trial: essential documents under ICH E6 must be filed on an ongoing basis; an incomplete TMF is one of the most common causes of GCP findings during inspections.
- A change in trial leadership without a structured handover: when the position is vacant, context, open actions, and the status with authorities are lost, which directly affects data quality and the timeline.
- CRO oversight without clear interfaces: responsibilities between sponsor and CRO are not delineated, so tasks fall through the cracks between the parties.
Services
How we support you
End-to-end trial leadership (Lead CPM)
Taking on full operational responsibility for a clinical trial across all phases: milestone and budget plan, resource control, communication with authorities, CRO management, and quality assurance through to documented study closure. Deliverable: trial leadership with ongoing status reporting against the milestone plan.
Site activation & recruitment management
Accelerating site initiation by parallelizing contract, ethics approval, and the initiation visit, plus setting up recruitment tracking against enrollment targets. Deliverable: site activation plan and recruitment tracker with defined escalation thresholds for slow investigator sites.
TMF management & GCP compliance
Setting up and maintaining the Trial Master File throughout the trial in line with ICH E6, ongoing compliance monitoring of trial administration, and preparation for audits and regulatory inspections. Deliverable: structured TMF with documented completeness review and inspection-readiness status.
Learn more →CRO selection & oversight
Delineating responsibilities between sponsor and CRO, defining handover points, and providing ongoing oversight in line with the sponsor's responsibilities under ICH E6. Deliverable: responsibility matrix and CRO oversight plan with defined reporting lines.
Learn more →Interim CPM & transition management
Bridging vacancies or changes in trial leadership by stepping into ongoing trials with a structured handover of context, open actions, and the status with authorities. Deliverable: handover protocol and updated project status with no break in the GCP documentation.
How we work together
What it comes down to
The bottleneck of a clinical trial shifts over its course, and good trial leadership means knowing where it will be before it gets there. At the start it is site activation: contract negotiation, ethics approval, and the initiation visit each have their own lead times, and running them sequentially adds them up into a delay that later returns as missing time during recruitment. Parallelizing these steps is therefore not acceleration for its own sake, but the prerequisite for keeping enrollment targets achievable on plan at all. In the middle of the trial, the Trial Master File becomes the critical point: it must be maintained throughout the trial in line with ICH E6, because a retroactively filled TMF can be spotted from filing dates and is one of the most common causes of GCP findings.
This is exactly where we step in: the project assessment makes visible at the outset which strand currently sits on the critical path, and defined escalation rules ensure that deviations surface while corrective action is still inexpensive. For trials involving medical devices, the framework of the Medical Device Regulation (EU) 2017/745 and ISO 14155:2020 applies, while for drug trials in the EU it is the Clinical Trials Regulation (EU) No 536/2014. The operational logic of control, oversight, and documentation maintained throughout the trial stays the same in both cases.
Our approach
Our approach
Step
Result
Project assessment
A review of the milestone plan, budget status, site status, and TMF completeness with a prioritized list of critical points.
Milestone & budget plan
A binding study plan with critical path, budget baseline, and defined escalation rules.
Site activation & recruitment
Activated investigator sites with ongoing recruitment tracking against enrollment targets.
Trial conduct & CRO oversight
Ongoing control against plan, documented CRO oversight, and a TMF maintained throughout the trial.
Inspection readiness
A TMF with verified completeness and trial administration ready for audits and regulatory inspections.
Study closure
Documented study close-out, an archive-ready TMF, and handover to the sponsor.
Common pitfalls
Where projects commonly fail
Site activation is handled sequentially.
Contract negotiation, ethics approval, and the initiation visit run one after another rather than in parallel, so the recruitment start slips by the sum of all the lead times. That time is missing at the end when enrollment targets need to be met.
The Trial Master File is only filled in just before the inspection.
Essential documents under ICH E6 must be filed throughout the trial; timestamps and filing dates make a retroactively populated TMF easy to spot, which leads to serious GCP findings.
Escalation rules are missing or kick in too late.
Without defined thresholds for recruitment slippage or budget variance, corrective action is taken once the critical path has already broken instead of while corrections are still inexpensive.
Responsibilities between sponsor and CRO are not delineated.
If the sponsor's responsibility under ICH E6 for CRO oversight goes unfilled, tasks fall between the parties and are worked by neither the sponsor nor the CRO.
The change in trial leadership happens without a structured handover.
When open actions, the status with authorities, and the documented study context are lost, gaps appear in the GCP documentation that only surface in the audit and are then expensive to remediate.
FAQ
Frequently asked questions
Sources
- ICH E6(R2) and ICH E6(R3): Guideline for Good Clinical Practice
- Regulation (EU) No 536/2014 (Clinical Trials Regulation), primary text
- Regulation (EU) 2017/745 (MDR): clinical investigations of medical devices
- ISO 14155:2020: Clinical investigation of medical devices for human subjects
- https://theentourage.de/expertise/clinical-project-management/ (existing page content, revised)
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Regulations & standards considered
- ICH E6(R2) (Good Clinical Practice)
- ICH E6(R3) (Good Clinical Practice)
- EU 536/2014 (Clinical Trials Regulation, CTR)
- EU 2017/745 (MDR): clinical investigations of medical devices
- ISO 14155:2020 (Clinical investigation of medical devices for human subjects)
- 21 CFR Part 312 (FDA, Investigational New Drug)
- 21 CFR Part 812 (FDA, Investigational Device Exemption)
Related topics
Clinical Monitoring →
On-site monitoring of investigator sites as part of trial conduct
CRO Support →
Selection and oversight of the CRO with clearly delineated sponsor responsibility
Good Clinical Practice →
GCP requirements under ICH E6 as the foundation of trial leadership
Clinical Compliance →
TMF review and inspection readiness for GCP inspections
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences